NCT01695668View on ClinicalTrials.gov

Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%

NACompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

February 28, 2015

Conditions
Dry Eyes
Interventions
DRUG

Lotemax

Ophthalmic corticosteroid. It decreases inflammation of the eye

DRUG

Restasis

Restasis is an immunosuppressive agent. Cyclosporine may reduce inflammation in the eye.

All Listed Sponsors
collaborator

Bausch & Lomb Incorporated

INDUSTRY

lead

University of Michigan

OTHER

NCT01695668 - Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5% | Biotech Hunter | Biotech Hunter